METHYLPHENIDATE
Clinical safety rating: safe
Animal studies have demonstrated safety
Methylphenidate is a central nervous system (CNS) stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their extracellular concentrations. It also acts as a dopamine and norepinephrine releaser. The therapeutic effect in ADHD is thought to be due to increased dopaminergic signaling in the prefrontal cortex.
| Metabolism | Methylphenidate is primarily metabolized via deesterification to ritalinic acid (inactive) by carboxylesterase enzymes (CES1A1 in the liver). Minor metabolism occurs via hydroxylation, oxidation, and conjugation. |
| Excretion | Renal: 90% (mostly as metabolites, primarily ritalinic acid), Fecal: <2%, Unchanged drug in urine: ~1% |
| Half-life | Immediate-release: 2–3 hours; Extended-release: 3–4 hours (drug), 6–8 hours (beaded forms). Context: Short half-life necessitates multiple daily dosing; sustained-release formulations prolong duration. |
| Protein binding | ~30% (primarily to albumin) |
| Volume of Distribution | 13–28 L/kg (high due to extensive tissue distribution) |
| Bioavailability | Oral immediate-release: 10–20% (extensive first-pass metabolism); Extended-release: comparable to IR. Transdermal: ~50–60% of total dose. |
| Onset of Action | Oral immediate-release: 30–60 minutes; Oral extended-release: 1–2 hours; Transdermal: 2 hours; Intravenous: 5–10 minutes |
| Duration of Action | Oral immediate-release: 3–5 hours; Oral extended-release: 8–12 hours; Transdermal: up to 12 hours (with patch). Clinical note: Duration insufficient for full-day coverage with IR; ER formulations designed for once-daily dosing. |
Oral: Initial 5 mg twice daily (before breakfast and lunch), increase by 5-10 mg weekly; usual dose 20-30 mg/day in divided doses; maximum 60 mg/day. Extended-release: 18-36 mg once daily; maximum 72 mg/day.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | GFR 30-89 mL/min: No adjustment recommended. GFR <30 mL/min: Use with caution; reduce dose by 50% due to potential accumulation. Hemodialysis: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use. |
| Pediatric use | Weight-based: 0.3-0.6 mg/kg/dose up to 0.8 mg/kg/day. Immediate-release: 2.5-5 mg twice daily initially; titrate by 2.5-5 mg weekly; maximum 60 mg/day. Extended-release (age ≥6): 18 mg once daily; titrate by 18 mg weekly; maximum 54 mg/day. |
| Geriatric use | Start at 2.5 mg twice daily; titrate slowly by 2.5-5 mg every 2-3 weeks; maximum 40 mg/day. Monitor for cardiovascular effects, anxiety, and insomnia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
MAOIs are contraindicated due to risk of hypertensive crisis May exacerbate pre-existing psychosis and cause peripheral vasculopathy.
| Breastfeeding | M/P ratio: 2.4. Excreted in breast milk; potential for infant agitation and insomnia. Avoid breastfeeding or use with caution, monitoring infant for adverse effects. |
| Teratogenic Risk | First trimester: Limited data; possible increased risk of congenital heart defects. Second and third trimesters: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome (irritability, feeding difficulties). |
| Fetal Monitoring |
■ FDA Black Box Warning
Methylphenidate has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Carefully consider the risks of abuse before prescribing, and monitor for signs of abuse and dependence during therapy.
| Common Effects | narcolepsy |
| Serious Effects |
["Hypersensitivity to methylphenidate or any component of the formulation","Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI","Glaucoma","Motor tics or a family history or diagnosis of Tourette's syndrome","Severe anxiety, tension, agitation","Pre-existing structural cardiac abnormalities or serious heart arrhythmias"]
| Precautions | ["Serious cardiovascular events including sudden death in patients with pre-existing cardiac abnormalities","Increased blood pressure and heart rate","Psychiatric adverse events such as psychosis or mania","Suppression of growth in children","Seizures","Priapism","Peripheral vasculopathy including Raynaud's phenomenon","Drug dependence and withdrawal upon abrupt discontinuation"] |
Loading safety data…
| Maternal: Blood pressure, heart rate, weight gain, and signs of abuse. Fetal: Ultrasound growth scans, fetal heart rate monitoring, and neonatal adaptation assessment at birth. |
| Fertility Effects | No direct evidence of impaired fertility; may cause menstrual irregularities and reduced libido in females, reversible upon discontinuation. |